Clinical Trials Browser

INDUSTRY × Esophageal Neoplasms × Irinotecan × Clear all

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Pancreatic Neoplasms

NCT05319730 2026-03-20

MK-3475-06B

Phase 1/2 Recruiting

230 enrolled

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT06607185 2026-03-13

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Phase 1 Active not recruiting

750 enrolled

GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT05342636 2025-12-17

A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)

Phase 1/2 Completed

90 enrolled

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT04415853 2025-05-18

Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer

Phase 3 Recruiting

416 enrolled

Gastrointestinal

Esophageal Neoplasms

NCT03099382 2024-01-22

Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer

Phase 3 Completed

457 enrolled 9 charts

Gastrointestinal

Esophageal Neoplasms

NCT03933449 2023-03-29

KEYNOTE-181

Phase 3 Completed

123 enrolled 25 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT02564263 2023-03-13

KEYNOTE-181

Phase 3 Completed

628 enrolled 27 charts 2 FDA

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT01822613 2020-12-19

Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC)

Phase 1 Completed

48 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT00813072 2012-03-02

Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma

Phase 2 Completed

135 enrolled

Gastrointestinal

Adenocarcinoma, Esophageal Neoplasms, Neoplasm Metastasis, Stomach Neoplasms

Clinical Trials

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

MK-3475-06B

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)

Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer

Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer

KEYNOTE-181

KEYNOTE-181

Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC)

Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma